Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Curr Alzheimer Res Year : 2012

Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.

Abstract

Recent data indicate that Tau immunotherapy may be relevant for interfering with neurofibrillary degeneration in Alzheimer disease and related disorders referred to as Tauopathies. The key question for immunotherapy is the choice of the epitope to target. Abnormal phosphorylation is a well-described post-translational modification of Tau proteins and may be a good target. In the present study, we investigated the effects of active immunization against the pathological epitope phospho-Ser422 in the THY-Tau22 transgenic mouse model. Starting from 3-6 months of age, THY-Tau22 mice develop hippocampal neurofibrillary tangle-like inclusions and exhibit phosphorylation of Tau on several AD-relevant Tau epitopes. Three month-old THY-Tau22 mice were immunized with a peptide including the phosphoserine 422 residue while control mice received the adjuvant alone. A specific antibody response against the phospho-Ser422 epitope was observed. We noticed a decrease in insoluble Tau species (AT100- and pS422 immunoreactive) by both biochemical and immunohistochemical means correlated with a significant cognitive improvement using the Y-maze. This Tau immunotherapy may facilitate Tau clearance from the brain toward the periphery since, following immunization, an increase in Tau concentrations was observed in blood. Overall, the present work is, to our knowledge, the first one to demonstrate that active immunotherapy targeting a real pathological epitope such as phospho-Ser422 epitope is efficient. This immunotherapy allows for Tau clearance and improves cognitive deficits promoted by Tau pathology in a well-defined Tau transgenic model.
Fichier principal
Vignette du fichier
TroquierLastVersion.pdf (599.06 Ko) Télécharger le fichier
inserm-00664452_edited.pdf (209.03 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Origin : Files produced by the author(s)
Loading...

Dates and versions

inserm-00664452 , version 1 (30-01-2013)

Identifiers

  • HAL Id : inserm-00664452 , version 1
  • PUBMED : 22272619

Cite

Laëticia Troquier, Raphaëlle Caillierez, Sylvie Burnouf, Francisco J. Fernandez-Gomez, Marie-Eve Grosjean, et al.. Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.: Active Tau immunotherapy. Curr Alzheimer Res, 2012, 9 (4), pp.397-405. ⟨inserm-00664452⟩

Collections

INSERM UNIV-LILLE
197 View
1026 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More